Pharmaceutical products used during medical scanning procedures to enhance images and provide information about the structure and functioning of organs, tissues and molecules in the body, for early, accurate diagnosis and management of heart disease, circulatory disorders, lung disease, brain disease and cancer.

Chromatography purification systems, membrane products and media used in the manufacture of biopharmaceuticals (any biologically derived drug, eg. insulin, vaccines, DNA-based medicines, monoclonal antibodies, interferon), and for the laboratory scale separation of proteins for research and drug development.

High throughput systems (instruments, reagents, software) for genomics (DNA sequencing, gene expression and gene variation), proteomics (study of proteins and their role in biological function), and bioassays (analysis of cellular processes in metabolism and disease, used for screening and testing of potential new drugs).

Sales (excluding Japan) up 11% to £382 million

Sales up 3% to £133 million

Sales up 4%^# to £192 million

VisipaqueTM posts record sales of £56 million, an increase of 32%, following NEPHRIC study on renal safety

Patented product sales up 22% to £197 million

Good progress in product development, seven products in phase III trials

Bioprocess sales up 10%, excluding speciality products

Sales affected by weakness in laboratory separations market in Europe

Stronger sales performance expected in second half

Restructuring ahead of plan delivering £7 million of cost savings in the first half; savings expected to be running at the rate of £35 million per annum by the end of 2004

Restructuring costs of £41 million charged to date

Strategic focus on protein analysis and cellular bioassays

^#Denotes ongoing business growth excluding discontinued products.